共 7 条
[1]
[2]
[3]
[4]
[5]
[6]
[7]
Long‐term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin‐1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized; double‐blind; placebo‐controlled trial.[J].GeorgeNuki;BarryBresnihan;Moraye B.Bear;DorothyMcCabe.Arthritis & Rheumatism.2002, 11

